Exploratory analysis of the impact of prior immune checkpoint inhibitor (ICI) on trastuzumab deruxtecan (T-DXd; DS-8201) clinical outcomes and biomarkers (BM) in DESTINY-Gastric01 (DG-01), a randomized, phase 2, multicenter, open-label study in patients (pts) with HER2+advanced gastric or gastroesophageal junction adenocarcinoma

被引：3
作者：
Shitara, Kohei
Bang, Yung-Jue
Iwasa, Satoru
Sugimoto, Naotoshi
Ryu, Min-Hee
Sakai, Daisuke
Chung, Hyun Cheol Cheol
Omuro, Yasushi
Kawakami, Hisato
Yabusaki, Hiroshi
Sakamoto, Yasuhiro
Nishina, Tomohiro
Inaki, Koichiro
Kuwahara, Yusuke
Suto, Fumitaka
Sugihara, Masahiro
Saito, Kaku
Kojima, Akihito
Yamaguchi, Kensei
机构：
[1] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan
[2] Seoul Natl Univ, Coll Med, Seoul, South Korea
[3] Natl Canc Ctr, Tokyo, Japan
[4] Osaka Int Canc Inst, Osaka, Japan
[5] Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South Korea
[6] Osaka Univ Hosp, Osaka, Japan
[7] Yonsei Univ, Coll Med, Yonsei Canc Ctr, Seoul, South Korea
[8] Tokyo Metropolitan Komagome Hosp, Tokyo, Japan
[9] Kindai Univ Hosp, Osaka, Japan
[10] Niigata Canc Ctr Hosp, Niigata, Japan
[11] Osaki Citizen Hosp, Osaki, Miyagi, Japan
[12] Natl Hosp Org Shikoku Canc Ctr, Matsuyama, Ehime, Japan
[13] Daiichi Sankyo, Tokyo, Japan
[14] Daiichi Sankyo, Basking Ridge, NJ USA
[15] JFCR, Canc Inst Hosp, Tokyo, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 04期
关键词：
D O I：
10.1200/JCO.2022.40.4_suppl.322
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
322
引用
收藏
页数：3
相关论文
共 34 条
  • [31] Primary analysis from DS8201-A-U105: A phase 1b, two-part, open-label study of trastuzumab deruxtecan (T-DXd) with nivolumab (nivo) in patients (pts) with HER2-expressing urothelial carcinoma (UC).
    Galsky, Matt D.
    Del Conte, Gianluca
    Foti, Silvia
    Yu, Evan Y.
    Machiels, Jean-Pascal H.
    Doger, Bernard
    Necchi, Andrea
    De Braud, Filippo G.
    Hamilton, Erika P.
    Hennequin, Audrey
    Van den Mooter, Tom
    Debruyne, Philip R.
    Moreno, Irene
    Arkenau, Hendrik-Tobias
    Tsuchihashi, Zenta
    Cheng, Fu-Chih
    Augustine, Bincy
    Cheng, Ben
    Barrios, Daniel
    Luftner, Diana
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [32] A randomized, open-label, multicenter, adaptive phase 2/3 study of trastuzumab emtansine (T-DM1) versus a taxane (TAX) in patients (pts) with previously treated HER2-positive locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma (LA/MGC/GEJC)
    Kang, Yoon-Koo
    Shah, Manish A.
    Ohtsu, Atsushi
    Van Cutsem, Eric
    Ajani, Jaffer A.
    van der Horst, Tina
    Harle-Yge, Marie-Laurence
    Piao, Yongzhe
    Althaus, Betsy
    Thuss-Patience, Peter C.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [33] Randomized, open-label, multicenter, phase III study of trastuzumab deruxtecan (T-DXd) with rilvegostomig vs standard of care (SOC) in first-line, human epidermal growth factor receptor 2 (HER2)-expressing, locally advanced or metastatic (LA/m) biliary tract cancer (BTC): DESTINY-BTC01
    Ikeda, M.
    Kuang, M.
    Oh, D-Y.
    Cohen, G.
    Raoufmoghaddam, S.
    Winter, M.
    Javle, M.
    ANNALS OF ONCOLOGY, 2024, 35 : S1501 - S1501
  • [34] Open-label, randomized, multicenter, phase 3 study evaluating trastuzumab deruxtecan (T-DXd) as first-line treatment in patients with unresectable, locally advanced, or metastatic non-small cell lung cancer (NSCLC) harboring HER2 exon 19 or 20 mutations (DESTINY-Lung04).
    Li, Bob T.
    Ahn, Myung-Ju
    Goto, Koichi
    Mazieres, Julien
    Padda, Sukhmani Kaur
    William, Nassib William
    Wu, Yi-Long
    Dearden, Simon
    Ragone, Alejandra
    Viglianti, Natasha
    Gasco, Amaya
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
1234